InvestorsHub Logo
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

Re: midastouch017 post# 1401

Friday, 03/31/2017 8:31:32 AM

Friday, March 31, 2017 8:31:32 AM

Post# of 2850
BioLineRx Prices $25 Million Underwritten Public Offering

TEL AVIV, Israel, March 31, 2017 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has priced an underwritten public offering of approximately 29.4 million American Depositary Shares ("ADSs"), each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS for gross proceeds of $25 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx. All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on April 5, 2017, subject to customary closing conditions. BioLineRx has granted the underwriters a 30-day option to purchase up to an additional approximately 4.4 million ADSs at the public offering price. BioLineRx anticipates using the net proceeds from the offering to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate purposes.

JMP Securities acted as sole book-running manager for the offering. H.C. Wainwright & Co., LLC acted as lead manager. Maxim Group acted as co-manager.

The ADSs will be issued pursuant to a shelf registration statement that was previously filed with, and declared effective by, the Securities and Exchange Commission ("SEC"). A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News